News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out Stephen Van Deventer on X.
Buss & family man. “The difference between good CEO & Great CEO. How CEO handles the storms” Chairman & CEO of @preveceuticals SEEK SAFE HARBOUR https://x.com/DeventerStephen
$PRVCF PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
https://www.newsfilecorp.com/release/158992
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.
Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the planning stage) that will be needed to support a successful initial IND and/or CTA submission.
Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
Authoring of the Investigational Brochure for the Client's lead peptide in the final indication of interest.
PreveCeutical has now commenced the clinical development on March 20, 2023. This work is being performed at our selected CRO's facilities in Australia.
Furthermore, the board of directors appointed a disclosure committee represented by Stephen Van Deventer, Dr Linnea Olofsson and Evan Ballantyne effective immediately.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "As we continue to meet further milestones, we are enthusiastic that this program has commenced as we plan to aggressively pursue the development so we may apply for IND (Investigative New Drug) status and complete the Phase 1 clinical trials."
|
Followers
|
23
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
392
|
|
Created
|
08/16/17
|
Type
|
Free
|
| Moderators | |||
Preveceutical starts trading on US OTC
2017-08-16 06:18 ET - News Release
Mr. Stephen Van Deventer reports
PREVECEUTICAL MEDICAL BEGINS TRADING ON THE OTC MARKET
Preveceutical Medical Inc. is quoting its common shares for trading on the OTC Pink market, under the symbol PRVCF.
In connection with the quotation of its shares on the OTC, the company is completing its filings for the quotation of its shares on the OTCQB market. The company has also made an application for its common shares to be DTC eligible and expects to receive this designation within the next 30 days.
Preveceutical's chairman and chief executive officer, Stephen Van Deventer, commented, "An OTC quotation will provide further liquidity for both existing and new shareholders and increase Preveceutical's presence in the United States."
About Preveceutical Medical Inc.
Preveceutical Medical is a health sciences company that develops innovative options for preventive therapies utilizing organic and nature identical products.
The company currently has one product available for sale, the CELLB9 immune system booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries.
We seek Safe Harbor.
